Formulations of protein molecules comprising iduronate 2-sulfatase

Inventors

Andersen, Dana • CATHERMAN, Adam • Giese, Tina • Kannan, Gunasekaran • Kariolis, Mihalis S. • Mahon, Cathal S. • Patel, Ankit

Assignees

Denali Therapeutics Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12667606-B2

Patent

Publication Date

2026-06-30

Expiration Date


Abstract

Certain embodiments provide a pharmaceutical composition comprising: a protein molecule comprising an ERT enzyme-Fc fusion polypeptide and a modified Fc polypeptide; a buffer; an isotonicity agent; a surfactant; and a stabilizer; wherein the pH of the pharmaceutical composition is about 5.5 to 7.0, as well as methods of use thereof.

Core Innovation

The disclosure concerns pharmaceutical formulations containing iduronate 2-sulfatase fused to an Fc-based enzyme transport vehicle or modified-Fc protein molecules intended to bind transferrin receptor and facilitate blood-brain-barrier transport. The compositions combine the protein molecules with a buffer and salt across a defined pH range, and may further include a surfactant, a sugar stabilizer, and methionine. Sequence, concentration, and formulation details are [procedural detail omitted for safety].

The disclosure describes liquid or lyophilized compositions for enzyme replacement therapy in lysosomal storage disorders, including Hunter syndrome. Phosphate and salts maintain the enzyme in a reversible inactive state to support stability, with formulation studies reporting favorable stability under refrigerated conditions alongside associated kits and administration methods. The problem identified in the background section is not explicitly described in patent.

Claims Coverage

The independent claims cover pharmaceutical compositions containing sequence-defined Fc fusion protein molecules, comprising two inventive features.

Fc fusion protein composition with a buffer and salt

The claim recites a pharmaceutical composition comprising two protein molecules defined by a first Fc polypeptide and a fusion polypeptide, together with a buffer and a salt across a defined pH range. Specified sequences, concentrations, and pH are [procedural detail omitted for safety].

Fc fusion protein composition with specified formulation components

The claim recites a pharmaceutical composition comprising two protein molecules defined by a first Fc polypeptide and a fusion polypeptide, together with sodium phosphate buffer, sodium chloride, a polysorbate surfactant, sucrose, and methionine. Specified component ranges, sequences, and pH are [procedural detail omitted for safety].

The independent claims cover pharmaceutical formulations comprising sequence-defined Fc fusion protein molecules formulated either with a buffer and salt across a stated pH range, or with additional specified components including sodium phosphate, sodium chloride, polysorbate, sucrose, and methionine.

Stated Advantages

The Fc-based enzyme transport vehicle is intended to bind transferrin receptor and facilitate blood-brain-barrier transport.

Phosphate and salts can maintain IDS in a reversible inactive state to support stability.

The formulation studies report favorable stability under refrigerated conditions.

Documented Applications

The compositions are described for enzyme-replacement treatment of lysosomal storage disorders, including Hunter syndrome.

The disclosure describes administration and kits associated with the compositions.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.